Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pancreas Cancer
100%
Pancreas Adenocarcinoma
52%
Germ Cell
37%
Overall Survival
31%
Malignant Neoplasm
25%
Diseases
24%
BRCA1
22%
BRCA Mutation
21%
Arm
17%
DNA Repair
17%
Chemotherapy
16%
Clinical Trial
16%
Tumor
14%
Neoplasm
14%
BRCA2
12%
Xenograft
12%
Olaparib
12%
Cancer Cell
12%
Radiosurgery
11%
Pancreatic Ductal Adenocarcinoma
11%
Platinum
10%
Personalized Medicine
10%
Colorectal Carcinoma
10%
Adverse Event
10%
Biological Marker
9%
Oncology
9%
Adenocarcinoma
9%
Abdominal Cancer
9%
Gastroesophageal Junction
9%
Phase II Trials
9%
PARP Inhibitor
9%
Celiac Plexus
8%
Disease Exacerbation
8%
Adjuvant Chemotherapy
7%
Progression Free Survival
7%
Placebo
7%
Cancer
7%
Magnetic Resonance Imaging
7%
Germline Mutation
7%
Hazard Ratio
7%
Monotherapy
6%
Ex Vivo
6%
Retrospective Study
6%
Metastatic Colorectal Cancer
6%
Colon Carcinoma
6%
Quality of Life
6%
Metastatic Carcinoma
5%
Analgesia
5%
4 Iodo 2,5 Dimethoxyamphetamine
5%
Ascites
5%
Keyphrases
Pancreatic Cancer
64%
Pancreatic Ductal Adenocarcinoma
53%
Germline BRCA mutation
25%
Tumor
21%
Germline
18%
Overall Survival
17%
Pancreatic Adenocarcinoma
17%
Olaparib
16%
Pembrolizumab
16%
BRCA2
15%
Metastatic Pancreatic Cancer
15%
Breast Cancer
15%
Advanced Solid Tumors
14%
Phase II Trial
13%
Chemotherapy
13%
BRCA mutation
13%
DNA Repair
12%
BRCA2 mutation
12%
PARP Inhibitors (PARPi)
11%
Previously Treated
11%
BRCA mutation Carriers
11%
Monotherapy
11%
Cancer Cells
10%
95% Confidence Interval
10%
BRCA-associated
10%
Median Overall Survival
10%
Gemcitabine
9%
Objective Response Rate
9%
Combination Therapy
9%
Clinical Trials
9%
Disease Progression
9%
Veliparib
8%
Cancer Patients
8%
Placebo
7%
Metastatic Pancreatic Adenocarcinoma
7%
Colorectal Cancer
7%
Germline mutation
7%
Cisplatin
6%
Homologous Recombination Deficiency
6%
Metastatic Colorectal Cancer (mCRC)
6%
Antitumor Activity
6%
Gastric Cancer
6%
Non-carriers
6%
Phase I Study
6%
Hazard Ratio
6%
Adjuvant Chemotherapy
6%
Gastroesophageal Junction Cancer
6%
Patient-derived Xenograft
6%
Genetic Modification
6%
Transforming Growth Factor-β
6%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
57%
Pancreas Adenocarcinoma
43%
Solid Malignant Neoplasm
27%
Chemotherapy Regimens
25%
Pembrolizumab
23%
Diseases
21%
Malignant Neoplasm
19%
Monotherapy
19%
Overall Survival
18%
Neoplasm
16%
Adverse Event
16%
Combination Therapy
14%
Gemcitabine
14%
Adenocarcinoma
10%
Colorectal Carcinoma
9%
Olaparib
9%
Small Interfering RNA
9%
Metastatic Colorectal Cancer
8%
Clinical Trial
8%
Phase II Trials
8%
Non Small Cell Lung Cancer
7%
Oxaliplatin
7%
Cisplatin
6%
Pharmacokinetics
6%
Placebo
6%
Progression Free Survival
6%
Abdominal Cancer
5%
Veliparib
5%
Mammalian Target of Rapamycin Inhibitor
5%
Nivolumab
5%
Somatomedin
5%
Fibrinogen
5%
Receptor Antibody
5%
Prodrug
5%
Abemaciclib
5%
Mitomycin
5%
Ascites
5%
Biological Marker
5%
Paclitaxel
5%